Parkside Advisors’s Abeona Therapeutics ABEO Stock Holding History

Parkside Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-581	Closed	-$31K	–	61
2020 Q1	$31K	Hold	581	–	–	0.02%	58
2019 Q4	$48K	Hold	581	–	–	0.02%	71
2019 Q3	$33K	Hold	581	–	–	0.02%	62
2019 Q2	$69K	Hold	581	–	–	0.04%	61
2019 Q1	$107K	Hold	581	–	–	0.06%	58
2018 Q4	$104K	Buy	581 +80	+16%	+$17.4K	0.06%	60
2018 Q3	$160K	Buy	+501	New	+$178K	0.11%	45
2018 Q1	–	Sell	-556	Closed	-$220K	–	38
2017 Q4	$220K	Hold	556	–	–	0.15%	34
2017 Q3	$237K	Hold	556	–	–	0.17%	33
2017 Q2	$89K	Buy	+556	New	+$75.9K	0.06%	38

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Parkside Advisors's ABEO Position: Q2 2020 in Review

Parkside Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2020, closing a stake of 581 shares — an estimated $31K sold.

Parkside Advisors first reported a position in ABEO in Q2 2017 and held it in 10 quarters. The position peaked at $237K in Q3 2017. 83 funds tracked by Wall St. Rank hold ABEO as of Q2 2020.

Parkside Advisors reported no remaining Abeona Therapeutics position as of Q2 2020 after selling out during the quarter.
Parkside Advisors sold 581 Abeona Therapeutics shares in Q2 2020, an estimated $31K.
Parkside Advisors first reported a position in Abeona Therapeutics in Q2 2017 and held it in 10 quarters.
Parkside Advisors's Abeona Therapeutics position peaked at $237K in Q3 2017.
83 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2020.

Based on Parkside Advisors's 13F filing for Q2 2020, filed 8 Jul 2020.